180 related articles for article (PubMed ID: 34472567)
1. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
Cohen OC; Ismael A; Pawarova B; Manwani R; Ravichandran S; Law S; Foard D; Petrie A; Ward S; Douglas B; Martinez-Naharro A; Chacko L; Quarta CC; Mahmood S; Sachchithanantham S; Lachmann HJ; Hawkins PN; Gillmore JD; Fontana M; Falk RH; Whelan CJ; Wechalekar AD
Eur Heart J; 2022 Jan; 43(4):333-341. PubMed ID: 34472567
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.
Salinaro F; Meier-Ewert HK; Miller EJ; Pandey S; Sanchorawala V; Berk JL; Seldin DC; Ruberg FL
Eur Heart J Cardiovasc Imaging; 2017 Sep; 18(9):1057-1064. PubMed ID: 27965280
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
4. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic score of cardiac involvement in AL amyloidosis.
Nicol M; Baudet M; Brun S; Harel S; Royer B; Vignon M; Lairez O; Lavergne D; Jaccard A; Attias D; Macron L; Gayat E; Cohen-Solal A; Arnulf B; Logeart D
Eur Heart J Cardiovasc Imaging; 2020 May; 21(5):542-548. PubMed ID: 31292624
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis.
Cohen OC; Sathyanath A; Petrie A; Ravichandran S; Law S; Manwani R; Foard D; Sachchithanantham S; Mahmood S; Martinez-Naharro A; Fontana M; Whelan CJ; Hawkins PN; Lachmann HJ; Gillmore JD; Wechalekar AD
Heart; 2022 Sep; 108(20):1616-1622. PubMed ID: 35764371
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy.
Aurich M; Bucur J; Vey JA; Greiner S; Aus dem Siepen F; Hegenbart U; Schönland S; Katus HA; Frey N; Mereles D
Open Heart; 2023 Jul; 10(2):. PubMed ID: 37463823
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
9. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
Ternacle J; Bodez D; Guellich A; Audureau E; Rappeneau S; Lim P; Radu C; Guendouz S; Couetil JP; Benhaiem N; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Mohty D; Deux JF; Damy T
JACC Cardiovasc Imaging; 2016 Feb; 9(2):126-38. PubMed ID: 26777222
[TBL] [Abstract][Full Text] [Related]
10. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
Sharpley FA; Fontana M; Martinez-Naharro A; Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Hawkins PN; Wechalekar AD
Haematologica; 2020 May; 105(5):1405-1413. PubMed ID: 31399529
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
12. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
13. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
[TBL] [Abstract][Full Text] [Related]
14. Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis.
Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Jeon ES
Sci Rep; 2019 May; 9(1):7746. PubMed ID: 31123293
[TBL] [Abstract][Full Text] [Related]
15. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
16. Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis.
Yu Y; Huang Z; Hu W; Li X; Shen M; Zhang J; Tang R; Chen S; Chen W
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):519-525.e1. PubMed ID: 32389672
[TBL] [Abstract][Full Text] [Related]
17. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.
Basset M; Milani P; Foli A; Nuvolone M; Benvenuti P; Nanci M; Fabris F; Bellofiore C; Merlini G; Palladini G
Blood; 2022 Nov; 140(18):1964-1971. PubMed ID: 35772003
[TBL] [Abstract][Full Text] [Related]
18. Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy.
Vitarelli A; Lai S; Petrucci MT; Gaudio C; Capotosto L; Mangieri E; Ricci S; Germanò G; De Sio S; Truscelli G; Vozella F; Pergolini MS; Giordano M
Int J Cardiol; 2018 Nov; 271():371-377. PubMed ID: 30049493
[TBL] [Abstract][Full Text] [Related]
19. Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic M; Kobayashi Y; Wheeler M; Barrett C; Liedtke M; Lafayette R; Schrier S; Haddad F; Witteles R
Am J Cardiol; 2017 Oct; 120(8):1381-1386. PubMed ID: 28844519
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]